AIM (AIM ImmunoTech) Float Percentage Of Total Shares Outstanding: 99.50% (As of Jun. 29, 2026)


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.30
GF Value $2.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Float Percentage Of Total Shares Outstanding?

AIM ImmunoTech AIM -5.09% 33 Float Percentage Of Total Shares Outstanding is 99.50% as of Jun. 29, 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AIM ImmunoTech's float shares is 27.58 Mil. AIM ImmunoTech's total shares outstanding is 27.72 Mil. AIM ImmunoTech's float percentage of total shares outstanding is 99.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AIM ImmunoTech's Insider Ownership is 78.63%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AIM ImmunoTech's Institutional Ownership is 2.29%.

AIM
33GF Score
AIM ImmunoTech Inc AIM
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AIM ImmunoTech's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=27.58/27.72
=99.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.50% mean?
AIM ImmunoTech (AIM) has a Float Percentage Of Total Shares Outstanding of 99.50% as of Jun. 29, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Float Percentage Of Total Shares Outstanding too high?
AIM ImmunoTech's current Float Percentage Of Total Shares Outstanding is 99.50%. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Float Percentage Of Total Shares Outstanding compare to RVPH and BOLT?
AIM ImmunoTech's Float Percentage Of Total Shares Outstanding of 99.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Float Percentage Of Total Shares Outstanding is 99.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.30 — trading 89% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.50%. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Float Percentage Of Total Shares Outstanding is 99.50% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.30 is trading 89% below its estimated GF Value™ of $2.69. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Float Percentage Of Total Shares Outstanding: 99.50%
  • GF Value™: $2.69 vs. price of $0.30 (89% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$2.69
GF Value